Jacqueline Barrientos, MD, MS


PI3K Inhibitors for CLL

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Sa Wang, MD, MD Anderson Cancer Center


Unmet Needs in SM Treatment

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Monica Peravali, MD


Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Christopher Jean-Louis, DO, MPH


Comprehensive Treatment Advances Care for Patients With Early-Stage Breast Cancer

Advances in the diagnosis and treatment of early-stage breast cancer highlight the need for clinicians to adapt to paradigm shifts that will have notable effects on patient care.

Dickran G. Kazandjian, MD


Dr. Kazandjian on the Potential Utility of BiTEs in Relapsed/Refractory Multiple Myeloma

Dickran G. Kazandjian, MD, discusses the potential utility of bispecific T-cell engagers in relapsed/refractory multiple myeloma.

Ira Braunschweig, MD


Dr. Braunschweig on Mitigating the Toxicities of CAR T-Cell Therapy in Lymphoma

Ira Braunschweig, MD, discusses mitigating ​the toxicities that are associated with CAR T-cell therapy in lymphoma.

M. Michele Blackwood, MD, FACS


The Future of Breast Cancer Surgery Is Here

Thanks to advances in research, targeted therapies, and a more personalized approach to treating patients diagnosed with breast cancer, more surgical options exist for patients with breast cancer patients than ever before.

Amanda Cass, PharmD, BCPS, BCOP


Dr. Cass on Managing Diarrhea in Patients Treated With EGFR TKIs

Amanda Cass, PharmD, BCPS, BCOP, discusses strategies to manage the diarrhea that may occur as an adverse effect in patients treated with EGFR TKIs.

Catherine Ann Shu, MD


NSCLC: Future Treatment Landscape of EGFR Exon 20 Insertion Mutations

Before closing out their discussion on EGFR exon 20 insertion mutations in NSCLC, experts share their thoughts on the future treatment landscape and potential unmet needs.

Mojun Zhu, MD


Dr. Zhu on Key Results From the TOPAZ-1 Trial in Biliary Tract Cancer

Mojun Zhu, MD, discusses key findings from the phase 3 TOPAZ-1 trial in patients with biliary tract cancer.

Erminia Massarelli, MD, PhD, MS


Dr. Massarelli on Unmet Needs in EGFR Exon 20–Mutated NSCLC

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in EGFR exon 20–mutated non–small cell lung cancer.

Neel P. Chudgar, MD


Beyond the Clinic: Leveraging Research to Tackle Lung Cancer Disparities

Lung cancer remains the most common cause of cancer death in the United States.

Tomer Mark, MD


Dr. Mark on ​Questions Regarding Sequencing in Multiple Myeloma

Tomer Mark, MD, discusses making sequencing decisions amid the array of available treatment options in multiple myeloma.

David Gerber, MD


Clinical Pearls and the Future of LEMS

Experts provide clinical pearls on treating Lambert-Eaton myasthenic syndrome and small cell lung cancer and share upcoming advances and trials they look forward to.

Puja S. Venkat


Dr. Venkat on Unmet Needs in Ovarian Cancer

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer. 

Yasir Y. Elamin, MD


Dr. Elamin on Poziotinib Efficacy and Mutation Insertion Location in NSCLC

Yasir Y. Elamin, MD, discusses the efficacy of poziotinib in patients with EGFR exon 20–mutated non–small cell lung cancer with near-loop vs far-loop mutations.

Bilal A. Siddiqui, MD


Dr. Siddiqui on Defining Characteristics of Nonmetastatic CRPC

Bilal A. Siddiqui, MD, discusses the nuances of defining the characteristics of nonmetastatic castration-resistant prostate cancer.

Nitya Raj, MD,


Dr. Raj on Injection Site Pain With Octreotide Long-Acting Release Vs Lanreotide in NETs

Nitya Raj, MD, discusses the results of a phase 4 trial comparing injection site pain with octreotide long-acting release vs lanreotide in well-differentiated neuroendocrine tumors.

Greg Nowakowski, MD, Mayo Clinic 


Exploring Emerging Data in DLBCL 

A panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.

Stephanie E. Weiss, MD, FASTRO


Dr. Weiss on Selecting Optimal Radiation Therapy for Brain Metastases

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Brandon Mahal, MD


Dr. Mahal on the Emerging Role of Epigenomics in Prostate Cancer

Brandon Mahal, MD, discusses the emerging role of epigenomics in prostate cancer.

Bruce Feinberg, DO


The COVID-19 Pandemic Will Have Long-Term Impact on Oncology Practices

The COVID-19 pandemic created new patient care challenges in oncology, such as how to reduce risks of virus exposure for patients who may be immunocompromised and switching from in-person visits to telemedicine.

Cleveland Clinic


Cleveland Clinic Appoints J. Joseph Melenhorst, PhD as Director of Cell Therapy and Immuno-Engineering Program, and Vice Chair of Center for Immunotherapy and Precision Immuno-Oncology

J. Joseph Melenhorst, Ph.D., has been appointed director of the new Cell Therapy and Immuno-Engineering Program, and Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

Robert J. Lewandowski, MD, FSIR


Real-World Evidence on Use of Immune Checkpoint Inhibitor Combinations and Clinical Trial Endpoints

Experts in liver cancer treatment provide insight on real-world trials of immune checkpoint inhibitor combinations in HCC and opine on trial endpoints when immune therapy is utilized.

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN


Dr. Neumann on Tapering Steroids in cGVHD

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Gary Ulaner, MD, PhD


Question and Answer Session

Dr Gary Ulaner and Dr Jeremy Force answer questions submitted by attendees of the live webinar discussing the role of various strategies to detect estrogen receptor (ER)-positive breast cancer, with particular focus on the role of 18-F FES-PET imaging in diagnosis and treatment of ER-positive breast cancer.

Wendy Stock, MD


Women in Oncology: Prioritization and Passionate Legacies

Selina M. Luger, MD, FRCPC, Gail J. Roboz, MD, and Wendy Stock, MD, discuss how being female affected their careers and share the scientific achievements they most want to be remembered for in the leukemia field.

Laura Finn, MD


Dr. Finn on the Utility of Belantamab Mafodotin in Late Relapsed Multiple Myeloma

Laura Finn, MD, discusses the utility of belantamab mafodotin-blmf in late relapsed multiple myeloma.

Vaishali Sanchorawala, MD


First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens

An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.